Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study.
Stefan Kasper(Essen University Hospital), François Ghiringhelli(Inserm), Dirk Arnold(Asklepios Klinik Altona), Howard S. Höchster(Rutgers, The State University of New Jersey), Violaine Randrian(Université de Poitiers), Arvind Dasari(The University of Texas MD Anderson Cancer Center), Ziji Yu(Takeda (United States)), Andrea Sartore‐Bianchi(University of Milan), Elena Élez(Vall d'Hebron Hospital Universitari), David Tougeron(Université de Poitiers), James C. Yao(The University of Texas MD Anderson Cancer Center), Sara Lonardi(Istituto Oncologico Veneto), Takayuki Yoshino(University of Tsukuba), William R. Schelman, Chiara Cremolini(University of Pisa), Alberto F. Sobrero(Ospedale Policlinico San Martino), Eric Van Cutsem, Cathy Eng(Vanderbilt University)
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k